Patentees await more post-Bilski decisions
The Federal Circuit’s decision to uphold Prometheus’s diagnostic method patents despite Bilski should elicit “a sigh of relief” from clinical and research diagnostic companies
But there are two more closely-watched cases that in part turn on the Federal Circuit's interpretation of the Supreme Court's Bilski ruling: Classen v Biogen and the Myriad case.
Classen v Biogen was remanded at the same time as Prometheus,...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.